Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Immediate release (IR) Paliperidone
Immediate release Paliperidone · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Immediate release (IR) Paliperidone | DRUG | - |
Inclusion Criteria: * Patients must have a diagnosis of schizophrenia or schizoaffective disorder as defined by DSM-IV criteria, with no exacerbation of psychosis for at least 3 months prior to screening * Patients must have a normal 12-lead ECG at screening and on Day -1, including: Normal sinus r...
Top 15 of 16 competitors
Immediate release paliperidone is a small molecule formulation of paliperidone developed by Johnson & Johnson (ticker: JNJ). It is being studied in schizophrenia, a psychiatric condition. The immediate release version is distinct from longer acting formulations because the drug is released promptly after administration rather than being gradually released over time.
Immediate release paliperidone is being studied for the treatment of schizophrenia. Johnson & Johnson (ticker: JNJ) is the developer of this formulation. The clinical program has focused on patients with schizophrenia, and one completed Phase 1 trial also enrolled patients with schizoaffective disorder alongside schizophrenia.
Johnson & Johnson, which trades under the ticker JNJ, is the developer of immediate release paliperidone. The company has sponsored the clinical research for this formulation, including a completed Phase 1 study evaluating cardiac QT and QTc intervals in patients with schizophrenia and schizoaffective disorder.
Immediate release paliperidone is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The completed study, NCT00791349, was a randomized, double blind evaluation of QT and QTc intervals in patients administered immediate release paliperidone.
Immediate release paliperidone has been evaluated in one completed Phase 1 trial, NCT00791349, titled A Study of QT and QTc Intervals in Patients Administered Immediate Release Paliperidone. The trial enrolled 141 patients with schizophrenia or schizoaffective disorder, was randomized and double blind, and included participants aged 18 years and older.
Yes, immediate release paliperidone is also known as immediate release (IR) paliperidone. The abbreviation IR refers to the same formulation, in which the drug is released promptly after administration. Both names refer to the small molecule developed by Johnson & Johnson (ticker: JNJ) for schizophrenia.